Early spinal surgery may indicate future ATTR-CM
Sixteen percent of patients developed transthyretin amyloid cardiomyopathy (ATTR-CM) within six years of surgery for lumbar spinal stenosis.
News
-
-
Current and future insights in ATTR-CM management
A recently published review summarized the advances in ATTR-CM screening, diagnosis and treatment and analyzed future perspectives.
-
Nex-Z receives Regenerative Medicine Advanced Therapy designation for ATTR-CM
Nex-z, a CRISPR/Cas9 therapy, was found to promote sustained and prolonged reduction of transthyretin levels in patients with ATTR-CM.
-
Biomarkers of worsening ATTR-CM identified in patients on tafamidis
NT-proBNP levels and oral diuretic use were associated with cardiac disease worsening in patients with ATTR-CM taking tafamidis.
-
Research program aims to improve diagnosis of ATTR amyloidosis
A research initiative combining two studies aims to improve early diagnosis and treatment for patients with ATTR amyloidosis.
-
Tafamidis improves ATTR-CM survival regardless of a patient’s age
Tafamidis can improve survival in octogenarian patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
-
Vutrisiran associated with better functional capacity in ATTR-CM
Vutrisiran appears to effectively conserve functional capacity and quality of life (QOL) in patients with ATTR-CM.
-
Acoramidis decreases hospitalization rate in ATTR-CM
A new study reports that treatment with acoramidis decreases the rate of all-cause mortality and cardiovascular hospitalization in patients with ATTR-CM.
-
Gene‑modulating therapies show promise in ATTR-CM
A recent review article explores a variety of therapies being developed to target the root cause of ATTR-CM.
-
Addressing disparities in ATTR-CM diagnosis and treatment key for better care
Barriers to care in ATTR-CM include disparities in diagnosis, treatment access, and awareness among medical professionals.
